Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants
- 1 October 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1186-1198
Abstract
Background: The implantable cardioverter-defibrillator (ICD) is effective for preventing sudden death in patients with hypertrophic cardiomyopathy. However, data on performance and complications of implanted ICDs over particularly long time periods to inform clinical practice is presently incomplete. Methods: The study cohort comprises 217 consecutive hypertrophic cardiomyopathy patients with primary prevention ICDs implanted before 2008 and followed for ≥10 years (mean 12±4; range to 31). Results: Patients were 38±17 years at implant and 45 (21%) experienced appropriate interventions terminating ventricular tachycardia/ventricular fibrillation. The majority of ICD discharges occurred ≥5 years after implant (29 patients; 64%), including ≥10 years in 16 patients (36%). Initial device therapy increased in frequency from 2.3% of patients at P =0.005). Inappropriate ICD shocks in 39 patients occurred most commonly P =0.02). Other major device complications including infection and lead fractures and dislodgement occurred in 27 patients (12%) but did not increase in frequency over follow-up after implant ( P =0.47). There were no arrhythmic sudden death events among the 217 patients with ICD. Conclusions: In hypertrophic cardiomyopathy, after a primary prevention implant, ICD therapy often followed prolonged periods of device dormancy and increased progressively in frequency over time, including one-third of patients with initial therapy after 5 to 9 years, and an additional one-third of patients at ≥10 years. Frequency of inappropriate shocks decreased over follow-up, likely reflecting standard changes in device programming, while occurrence of device complications, such as lead fractures/infection, did not increase during follow-up.Keywords
This publication has 39 references indexed in Scilit:
- Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: Patient outcomes, rate of appropriate and inappropriate interventions, and complicationsAmerican Heart Journal, 2013
- Reduction in Inappropriate Therapy and Mortality through ICD ProgrammingNew England Journal of Medicine, 2012
- Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic CardiomyopathyCirculation: Heart Failure, 2012
- Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategyEuropean Heart Journal, 2011
- Inappropriate Implantable Cardioverter-Defibrillator ShocksJACC, 2011
- Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathyHeart, 2009
- Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 YearsCirculation, 2007
- Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator PatientsCirculation, 2005
- Temporal aspects of improved survival with the implanted defibrillator (MADIT-II)The American Journal of Cardiology, 2004
- American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice GuidelinesEuropean Heart Journal, 2003